VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine
Vaccine Information
  • Vaccine Name: C. muridarum PmpG-1, PmpE/F-2, and MOMP Proteins Vaccine
  • Target Pathogen: Chlamydia muridarum
  • Vaccine Ontology ID: VO_0004257
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Chlamydia proteins PmpG-1, PmpE/F-2, and MOMP (Yu et al., 2010).
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0001334
    • Description: Abisco-100
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: C57BL/6 and BALB/c
  • Vaccination Protocol: Mice were vaccinated 3 times subcutaneously with PmpG-1 plus PmpE/F-2 plus MOMP plus AbISCO-100 (G+F+M+AbISCO) (Yu et al., 2010).
  • Challenge Protocol: Two weeks after the final immunization, the mice in the three animal trials described above were then challenged with live EBs for protection evaluation (Yu et al., 2010).
  • Efficacy: The combination of three Chlamydia proteins formulated with AbISCO exhibited significant protection at day 13 compared to the group with adjuvant alone (Yu et al., 2010).